503A vs. 503B: The Legal and Regulatory Distinction, Explained From Source Documents
503A and 503B were created by the Drug Quality and Security Act of 2013 after the NECC outbreak killed 64 people. A statutory comparison of the two frameworks — drawn directly from 21 U.S.C. §§ 353a and 353b — and why the distinction determines the GLP-1 compounding policy debate.
The regulatory distinction between 503A and 503B compounding frameworks is central to every policy debate about compounded GLP-1 medications — yet it is routinely conflated in consumer media. Here's the distinction drawn directly from FDA regulatory text and the Federal Food, Drug, and Cosmetic Act.
The Statutory Framework
Sections 503A and 503B were added to the Federal Food, Drug, and Cosmetic Act (FD&C Act) by the Drug Quality and Security Act of 2013 (DQSA), enacted in response to the 2012 New England Compounding Center fungal meningitis outbreak that killed 64 people. The outbreak arose from a 503A pharmacy operating at 503B scale without 503B oversight — the legislative goal was to create separate regulatory pathways for different scales and types of compounding.
503A: Traditional Compounding Pharmacies
| Feature | 503A Requirements |
|---|---|
| Prescription requirement | Must have valid individual patient prescription |
| Batch production | Anticipatory compounding limited; primarily based on prescriptions in hand |
| Interstate distribution | Permitted only in limited circumstances |
| FDA inspection | Subject to FDA oversight; primary oversight is state pharmacy board |
| Essentially a copy prohibition | May not compound essentially a copy of commercially available drug |
| Shortage exemption | May compound drugs on FDA shortage list |
503B: Outsourcing Facilities
| Feature | 503B Requirements |
|---|---|
| Prescription requirement | Not required — may produce without individual prescriptions |
| Batch production | Large-scale batch permitted and expected |
| Interstate distribution | Permitted; can supply hospitals, clinics, pharmacies nationwide |
| FDA inspection | Subject to regular FDA inspection; cGMP standards apply |
| Essentially a copy prohibition | May not compound essentially a copy of commercially available drug (no shortage exemption) |
| Shortage exemption | No blanket shortage exemption — 503B cannot compound during shortage without additional FDA action |
503B outsourcing facilities are the primary supply source for compounded semaglutide and tirzepatide at scale — they produce in bulk for telehealth platforms that serve tens of thousands of patients. The 503B prohibition on 'essentially a copy' drugs without a shortage exemption is the provision that the FDA's June 2026 guidance proposal seeks to enforce. With semaglutide and tirzepatide removed from the shortage list, the 503B basis for large-scale compounding no longer exists under the statute. The 503A pathway remains — individual patient prescriptions from licensed prescribers — but cannot supply the volume that telehealth platforms require.
Enforcement History
FDA enforcement of compounding regulations has historically focused on the most egregious 503A violations — facilities operating at 503B scale without 503B registration. Enforcement of the "essentially a copy" prohibition against 503A pharmacies is less common; state pharmacy boards are the primary enforcement mechanism for individual pharmacy behavior. No major enforcement action against a 503A pharmacy specifically for compounding semaglutide has been publicly announced as of this writing.
Looking for a GLP-1 provider?
Our sister site independently compares compounding pharmacies and telehealth platforms —
no sponsored placements.
Sources
- 21 U.S.C. § 353a. Federal Food, Drug, and Cosmetic Act, Section 503A.
- 21 U.S.C. § 353b. Federal Food, Drug, and Cosmetic Act, Section 503B.
- Drug Quality and Security Act (P.L. 113-54). 2013.
- FDA. "503B Outsourcing Facilities." FDA.gov/drugs/human-drug-compounding/503b-outsourcing-facilities.